Stock information

General information

Total Shares Issued (as of November 30, 2021) 34,231,943
Designated Sponsor/Market Maker: Oddo Seydler Bank AG
Reuters: MORG.DE
Bloomberg MOR:GR
Paying Agent Deutsche Bank AG
Global Securities Services
lssuer Services / Post IPO Seruices
Taunusanlage 12
60325 Frankfurt am Main

listing in Germany

Stock Exchange: Frankfurt, Germany (Prime Standard)
Index: SDAX & TecDAX
SE Code: MOR
Security Code Number: 663 200
ISIN (International Security Identification Number): DE0006632003
1st Trading Day: March 9, 1999 (Neuer Markt)

Listing in the u.s.

Stock Exchange: Nasdaq
SE Code: MOR
CUSIP: 617760202
1st Trading Day: April 19, 2018
Security Paper: American Depositary Shares (ADS)
Ratio: 4 ADS = 1 Ordinary Share


Share price performance

The 2020 trading year was characterized by historically unusual high volatility. Following the outbreak of the COVID 19 pandemic, numerous stock indices around the world fell, often to multi-year lows, but turned around and recovered as the year progressed. At the end of 2020, many were even trading close to their multi-year or even all-time highs. The DAX index closed the year with a year-on-year gain of just under 4 %, the TecDAX rose by almost 7 %, and the MDAX increased by just below 9 %. The NASDAQ Biotechnology Index closed the year almost 26 % higher than at the beginning of the year as companies in the biotechnology sector were able to decouple themselves from the general stock market trend – as the importance of the biotechnology industry was reinforced by the pandemic.

MorphoSys AG shares have been trading on the Frankfurt Stock Exchange since 1999. In 2018, MorphoSys issued American Depositary Shares (ADSs*) on the U.S. NASDAQ exchange based on MorphoSys’ common stock. The Company’s ticker symbol is “MOR” on both exchanges.

MorphoSys’ shares opened the 2020 trading year in Xetra trading at € 129.60. The share performance was highly volatile, particularly in the first quarter of 2020. Following the announcement of the collaboration and licensing agreement with Incyte, the share price on Xetra increased temporarily and almost reached the all-time high of € 148.13 recorded in 2000. In the wake of the COVID 19 pandemic, the share price saw intraday declines as low as € 65.25, but was able to recover. MorphoSys’ shares started to stabilize in May, climbing to above € 100.00 and ended the trading year on Xetra at € 93.82.

Liquidity and Index Membership

The average daily trading volume of the MorphoSys share across all regulated trading platforms increased significantly to € 33.5 million in 2020 (previous year: € 25.6 million), corresponding to a year-on-year increase of more than 30 %. For the TecDAX and MDAX selection indices, trading volumes were up year-on-year by 28 % and 47 %, respectively. In the TecDAX, MorphoSys ranked 11th in terms of trading volume at year-end 2020 (unchanged from the previous year) and 13th in terms of market capitalization (previous year: 9th). In the MDAX, MorphoSys ranked 64th in terms of market capitalization (previous year: 55th) and 54th in terms of trading volume (2019: 57th). The rankings refer to the TecDAX30 and MDAX60 companies, respectively. MorphoSys is also a component of the NASDAQ Composite Index through its ADS program and is included in various other indices, such as the NASDAQ Health Care Index, the Loncar Cancer Immunotherapy Index and the S-Network Medical Breakthrough Index.

In addition to the trading on the regulated platforms, an average of approximately 217,000 of MorphoSys‘ shares with a value of approximately € 22.4 million were traded daily on alternative trading venues (“dark pools”) in 2020 (2019: 196,000 shares; € 19.1 million). This figure corresponds to a year-on-year increase in trading outside of the regulated markets of approximately 18 %. The MorphoSys ADSs reached a volume of US$ 3 million per trading day in the reporting year (previous year: US$ 1.7 million), for an increase of approximately 73 %.


Key data for the MorphoSys Share (As of December 31)

  2020 2019 2018 2017 2016
Total stockholders´ equity (in million €) 629.2 394.7 488.4 358.7 415.5
Number of shares issued (number) 32,890,046 31,957,958 31,839,572 29,420,785 29,159,770
Market capitalization (in million €) 3,086 4,052 2,832 2,253 1,422
Closing price in € (Xetra) 93.82 126.80 88.95 76.58 48.75
Average daily trading volume (in million €) 33.5 25.6 22.5 15.6 9.7
Average daily trading volume (in % of common stock) 0.98 0.81 0.77 0.83 0.78

Recent voting rights notifications

  1. 25/11/2021
  2. 12/11/2021
  3. 10/11/2021
  4. 09/11/2021
  5. 22/10/2021
  6. 21/10/2021
  7. 20/10/2021
  8. 19/10/2021
  9. 18/10/2021
  10. 18/10/2021
  11. 04/10/2021
  12. 01/10/2021
  13. 29/09/2021
  14. 27/09/2021
  15. 24/09/2021
  16. 23/09/2021
  17. 23/09/2021
  18. 23/09/2021
  19. 23/09/2021
  20. 23/09/2021
  21. 23/09/2021
  22. 20/09/2021
  23. 20/09/2021
  24. 20/09/2021
  25. 31/08/2021
  26. 27/08/2021
  27. 27/08/2021
  28. 25/08/2021
  29. 20/08/2021
  30. 18/08/2021
  31. 12/08/2021
  32. 02/08/2021
  33. 02/08/2021
  34. 02/08/2021
  35. 30/07/2021
  36. 21/07/2021
  37. 21/07/2021
  38. 21/07/2021
  39. 30/06/2021
  40. 24/06/2021
  41. 07/06/2021
  42. 20/05/2021
  43. 18/05/2021
  44. 18/05/2021
  45. 17/05/2021
  46. 17/05/2021
  47. 14/05/2021
  48. 04/05/2021
  49. 29/04/2021
  50. 26/04/2021
  51. 19/04/2021
  52. 25/02/2021


Institution Contact
Barclays Ms. Rosie Turner
Berenberg Mr. Zhiqiang Shu
Bryan Garnier Mr. Victor Floc'h
Citi Mr. Vineet Agrawal
Deutsche Bank Mr. Rajan Sharma
EQUI.TS Mr. Thomas Schießle
Frankfurt Main Research AG Mr. Mohamad Vaseghi 
Goldman Sachs Mr. Keyur Parekh  
HSBC Bank Ms. Julie Mead
Independent Research GmbH Mr. Tobias Gottschalt
JMP Securities Mr. Jason Butler
J.P.Morgan Cazenove Mr. James Gordon
Kempen & Co. Ms. Suzanne van Voorthuizen
Landesbank Baden-Württemberg Mr. Timo Kürschner
Leerink Mr. Geoffrey Porges
Stifel Mr. Marcus Wieprecht
Morgan Stanley  Mr. James Quigley
ODDO BHF Mr. Daniel Wendorff


Any opinions, forecasts, estimates, projections or predictions regarding MorphoSys’s performance made by the analysts are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of MorphoSys or its management. By providing the names of the analysts or certain information from them, MorphoSys does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. MorphoSys assumes no liability for the accuracy of such information and undertakes no obligation to update it if it is not aware of changes.


American Depositary Shares



Security Paper: American Depositary Shares (ADS)
Ratio: 4 ADSs = 1 ordinary share
U.S. Security Code (Cusip): 617760202
Trading Symbol: MOR
Depositary Bank: The Bank of New York
Local Custodian Bank: The Bank of New York Mellon SANV

ADS administration

All enquiries on ADS holdings should be made to:

BNY Mellon Shareowner Services
PO Box 505000
Louisville, KY 40233-5000
Phone: +1 201 680 6825
Toll free (in the US): +1-888-BNY-ADRS (+1-888-269-2377)

Share Buy-Back

Share Buy-Back March 2016

The Management Board of MorphoSys AG announced on February 24, 2016 with the approval of the Supervisory Board the decision to repurchase its own shares over the stock market for a total purchase price of up to EUR 2.18 million (excluding ancillary costs). The share buy-back will take place between March 3 and March 10, 2016, and is based on the authorization of the Annual General Meeting on May 23, 2014. On the basis of the current share price (EUR 37.47; Xetra closing price as of February 23, 2016), the total purchasing volume amounts to up to 58,179 shares or 0.22% of the registered share capital of the Company.

The Company intends to use the shares for its long-term incentive programs for its Executive Board and the Senior Management Group, but the shares can also be used for all other legally permitted purposes stated in the authorization of the Annual General Meeting of 2014.

The relevant conditions of the shareholders' resolution passed in the Annual General Meeting 2014 on the authorization to acquire and to use its own shares shall apply. The purchase price paid per share may not be more than 10% higher or 20% lower than the Company's share price determined by the opening auction in the Xetra trading system on the day of trading.

The share buy-back has been handled independently of and uninfluenced by the Company through an appointed bank in compliance with the safe-harbor provisions.

The share buy-back program in 2016 was completed on March 4th. Thereby 52,295 shares in total were acquired.


Overview Share Buy-Back Program March 2016

Date Number of Shares Average Price in € Purchased Volume in €
March 3, 2016 13,043 42.483 554,105.77
March 4, 2016 39,252 41.421 1,625,857.09
Total 52,295 41.686 2,179,962.86